Sign In
7 Oct 2008 07:00
ο»Ώ
7 OCTOBERΒ 2008
BYOTROL PLCΒ
HEALTHCARE UPDATE
MAJOR TRIAL IN NHS HOSPITAL ANDΒ USΒ HOSPITAL GOES SUPER BUG FREE
Byotrol plc (theΒ "Company") is pleasedΒ to provide a progress update in the healthcare sector.
In partnership with Synergy Health Plc,Β who licensed Byotrol's anti-microbial technology,Β andΒ supportingΒ this deployment into the NHS, the Company is pleased to report it hasΒ encouraging interim results from a large scale NHS trial at one of theΒ UK's leading University hospitals.Β
Byotrol technologyΒ incorporated into Synergy's Azo range of Hospital hygiene products,Β is currently being evaluated atΒ a leading teaching hospital inΒ the North WestΒ of EnglandΒ and the study is being supervised by TrusTECH, the NHS's innovation hub in theΒ North West. The purpose of this study is toΒ compare Byotrol with a standard cleaning regime in a clinical setting. ThisΒ will support the wide scale deployment of Byotrol technology into the NHS inΒ 2009. This trial follows theΒ highly successful study into the performance of Byotrol technology at the Glasgow Royal Infirmary in 2006.
Preliminary results including twelve weeks of dataΒ are planned to beΒ published in early December andΒ according to Richard DeedΒ of TrusTECH, "The early results are extremely encouraging whenΒ compared toΒ chlorine basedΒ cleaning. One of the biggest challenges facing the NHS at the moment is to find a technology that offers the biocidal performance of chlorine based products without the damage to equipment & fabric associated with using such products. If the results from this study continue to follow the trends shown to date, Byotrol could well be the answer to this challenge."
The Company is also pleased to be able to report that following deployment two years ago of the Byotrol technology in the Monroe Hospital in Bloomington, Indiana, North America, the hospital has recorded no cases of healthcare acquired infection over the past 24 months. The Company believes this is a significant success and demonstrates the power of the Byotrol technology over an extended period of time
Β
MonroeΒ HospitalΒ treats around 13,000 patientsΒ annuallyΒ and wouldΒ ordinarilyΒ be at high risk ofΒ healthcare acquired infection (HCAI)Β because it undertakesΒ 3,000 bone and joint surgical procedures including hip replacements every year, with many of these being undertaken on older patients.Β
MonroeΒ HospitalΒ isΒ usingΒ ByotrolΒ inΒ severalΒ ways.Β All hospital visitors have to sanitise their hands with ByotrolΒ hand foam on entry.Β Staff have incorporatedΒ Byotrol into their hand hygiene regimes and because the product is alcohol free, it does not dry or crack hands.Β Byotrol isΒ used to clean hard surfaces and impregnated wipesΒ are used to clean high contact surfaces. Additionally, theΒ hospital exteriorΒ is sprayed annuallyΒ with ByotrolΒ whichΒ also preventsΒ growth of algae on stonework.Β
Fred Price, President and Chief Executive Officer, ofΒ MonroeΒ said. "With healthcare career roots of 20 years, I have witnessed trends in anti-microbial solutionsΒ to protect patients, healthcare providers and the environment. Infection rates have historically been measured by minimising the risk with an acceptable percentage of infection. That is nowΒ history atΒ MonroeΒ HospitalΒ and byΒ partnering with Byotrol we have maintained a zero infectionsΒ environmentΒ sinceΒ openingΒ our doors 24 months ago. I cannot understand why every healthcare entity that comes in contact with patientsΒ doesn'tΒ use Byotrol? Our patientsΒ depend upon us to be "bug" free."
Stephen Falder, Deputy ChairmanΒ of ByotrolΒ says, "We areΒ delightedΒ with theΒ achievementΒ atΒ MonroeΒ as well asΒ the interim results we have received with the NHS study in theΒ North West.Β Β We now have a clear example of what can be achieved using Byotrol in a demanding healthcare situation. Having two infection free years in aΒ busyΒ hospitalΒ shows what can be achieved and will give real hope to those involved in managing down infections in NHS hospitals.Β
-EndsΒ -
For further information:
Jim RothnieΒ
McCann Erickson Communications House
T: 0044 (0)1625 822540
E:jim.rothnie@europe.mccann.com
Philip Davies
Charles Stanley Securities (Nominated Adviser)
T: 0044 (0)207 149 6457
Follow the stocks
